Study record
Mannick et al. 2014 low-dose everolimus / influenza vaccine response trial
Influenza vaccine antibody response
Human — Older adults enrolled in the Mannick 2014 trial Tier 2 · Human clinical/functional RCT verification: verified
1. Species / populationOlder adult humans, Mannick 2014 trial
2. Exposure, route, scheduleEverolimus 0.5 mg daily or 5-20 mg weekly, oral, 6 weeks
3. Comparator & durationPlacebo, 6 weeks dosing + vaccination challenge
4. Endpoint & numeric resultInfluenza vaccine antibody response improved ~20% vs placebo
5. What this study did NOT establishNo lifespan data; no long-term (beyond 6-week) safety or efficacy data
Full record
| Intervention(s) | Everolimus |
| Species | Human |
| Population | Older adults enrolled in the Mannick 2014 trial |
| Sample size | not specified in source participants verification: verified_2026-07-11 |
| Exposure | 0.5 mg daily OR 5-20 mg weekly mg everolimus, oral — 6 weeks dosing prior to influenza vaccination verification: verified_2026-07-11 |
| Comparator | Placebo |
| Duration | 6 weeks dosing + post-vaccination follow-up |
| Endpoint | Influenza vaccine antibody response |
| Evidence tier | Tier 2 · Human clinical/functional RCT |
| What was NOT established | Did not test lifespan or mortality. A 6-week dosing period and vaccine-response endpoint do not establish long-term safety or efficacy of chronic low-dose everolimus for immune enhancement. |
Result values (as reported in sourcing brief)
| vaccine response change | +~20% relative to placebo |
| interpretation | Improved immune-function endpoint; not a lifespan or mortality endpoint |
| verification | verification: verified_2026-07-11 |
Source citation
Verification status: verified This record was checked against its primary publication on 2026-07-11. PubMed/PMC/Lancet lookup; numbers cross-checked against abstract.Identifiers: PMID verified; DOI verified; PMC not reported; trial registry ID not reported. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that does not apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
| trial name | Mannick 2014 |
| pmid | 25540326 verified |
| doi | 10.1126/scitranslmed.3009892 verified |
| journal | Science Translational Medicine 2014;6:268ra179 |
| trial registry id | not reported not reported |
| authors | Mannick JB, Del Giudice G, Lattanzi M, et al. |
| year | 2014 |
| verified date | 2026-07-11 |
| verified method | PubMed/PMC/Lancet lookup; numbers cross-checked against abstract |
| verified note | RAD001 (everolimus) 6 wk; +~20% influenza-vaccine response at well-tolerated doses; reduced PD-1+ T cells — MATCHES. |
| verification status | verified |
Funding / conflict of interest
not compiled in this proof-of-concept verification: verified_2026-07-11
Version 0.2.0-mvp · literature search date 2026-07-11 · editorial owner Nabus Research